[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,432,018
  • Shares Outstanding, K 251,355
  • Annual Sales, $ 2,320 M
  • Annual Income, $ 782,570 K
  • EBIT $ 937 M
  • EBITDA $ 966 M
  • 60-Month Beta 0.38
  • Price/Sales 5.39
  • Price/Cash Flow 16.42
  • Price/Book 6.45

Options Overview Details

View History
  • Implied Volatility 35.57% (+0.55%)
  • Historical Volatility 44.53%
  • IV Percentile 41%
  • IV Rank 21.06%
  • IV High 71.05% on 10/17/25
  • IV Low 26.11% on 06/06/25
  • Expected Move (DTE 2) 1.79 (3.48%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,110
  • Volume Avg (30-Day) 926
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 30,478
  • Open Int (30-Day) 26,896
  • Expected Range 49.51 to 53.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.76
  • Number of Estimates 5
  • High Estimate $0.80
  • Low Estimate $0.68
  • Prior Year $0.65
  • Growth Rate Est. (year over year) +16.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.50 +17.91%
on 05/04/26
51.48 -0.37%
on 05/13/26
+6.33 (+14.08%)
since 04/13/26
3-Month
39.71 +29.16%
on 03/02/26
51.48 -0.37%
on 05/13/26
+7.37 (+16.78%)
since 02/13/26
52-Week
33.76 +51.95%
on 10/20/25
51.48 -0.37%
on 05/13/26
+14.34 (+38.81%)
since 05/13/25

Most Recent Stories

More News
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

- Presentations to be webcast on www.exelixis.com -

EXEL : 51.29 (+3.70%)
Exelixis: Q1 Earnings Snapshot

Exelixis: Q1 Earnings Snapshot

EXEL : 51.29 (+3.70%)
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted...

EXEL : 51.29 (+3.70%)
Exelixis Reports Tomorrow With Competitive Questions It Has Not Yet Answered

Barchart Research What to Expect from EXEL Earnings EXEL Generated May 4, 2026 Current Price $44.17 EPS Estimate $$0.67 Consensus Rating Moderate Buy Average Move 9.60% Exelixis Reports Tomorrow With Competitive...

EXEL : 51.29 (+3.70%)
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 51.29 (+3.70%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

- Presentations to be webcast on www.exelixis.com -

EXEL : 51.29 (+3.70%)
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?

Exelixis beats earnings estimates as Cabometyx drives profits and zanzalintinib positions the biotech for a major oncology expansion

EXEL : 51.29 (+3.70%)
Exelixis: Q4 Earnings Snapshot

Exelixis: Q4 Earnings Snapshot

EXEL : 51.29 (+3.70%)
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – ...

EXEL : 51.29 (+3.70%)
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results...

EXEL : 51.29 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 53.84
2nd Resistance Point 52.66
1st Resistance Point 51.97
Last Price 51.29
1st Support Level 50.11
2nd Support Level 48.93
3rd Support Level 48.25

See More

52-Week High 51.48
Last Price 51.29
Fibonacci 61.8% 44.71
Fibonacci 50% 42.62
Fibonacci 38.2% 40.53
52-Week Low 33.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.